CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

Johannes Sam(Roche (Switzerland)), Pablo Umaña(Zurich Insurance Group (Switzerland)), Sven Kronenberg(Roche (Switzerland)), Candice Jamois(Roche (Switzerland)), Martin Lechmann(Roche (Switzerland)), Jan Eckmann(Roche Pharma AG (Germany)), Samuel Gebhardt(Roche (Switzerland)), Sylvia Herter(Roche (Switzerland)), Stephan Gasser(Roche (Switzerland)), Thomas Höfer(Heidelberg University), Miro J. Eigenmann(Roche (Switzerland)), Sara Colombetti(Roche (Switzerland)), Miriam Bez(Roche (Switzerland)), Marine Le Clech(Roche (Switzerland)), Silvia Jenni(University Children's Hospital Zurich), Esther Bommer(Roche (Switzerland)), Sabine Wilson(Roche (United Kingdom)), Daniel Marbach(SIB Swiss Institute of Bioinformatics), Dario Speziale(Roche (Switzerland)), Florian Limani(Roche (Switzerland)), Koorosh Korfi(Queen Mary University of London), Ahmet Varol(Roche (Switzerland)), Christina Claus(Roche (Switzerland)), Birte Appelt(Roche (Switzerland)), Guy Georges(Roche Pharma AG (Germany)), Jenny Tosca Thom(Roche (Switzerland)), Leo Kunz(Center for Pediatric Endocrinology Zurich), Christian Klein(Roche (Switzerland)), Stefanie Briner(Roche (Switzerland)), Joana Marinho(Roche (Switzerland)), Christine Kuettel(Roche (Switzerland)), Katharina Lechner(Roche (Switzerland)), Valeria Nicolini(Roche (Switzerland)), Sreenath M. Krishnan(Roche (Switzerland)), Anne Schoenle(Roche (Switzerland)), Jean-Baptiste Pierre Vallier(Roche (Switzerland)), Carina Hage(Roche Pharma AG (Germany)), Brenda Gaillard(Roche (Switzerland)), Marina Bacac(Roche (Switzerland))
Blood
March 4, 2024
Cited by 40


Related Papers